Indications and Usage

Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.

Side effects needing medical attention

Black, tarry stools; bleeding gums; blood in urine or stool; blurred vision; body aches or pain; burning, crawling, itching, numbness, prickling, "pins and needles," or tingling feelings; chest pain or tightness in chest; chills; confusion; faintness or lightheadedness when getting up from a lying or sitting position suddenly; cough; decreased urination; difficult or labored breathing or shortness of breath; dry mouth; fainting; fever; headache; increase in heart rate; loss of voice; lower back or side pain; nasal or ear congestion or runny nose, sneezing or sore throat; pale skin; painful or difficult urination; painful blisters on trunk of body; pinhead-sized red spots on skin; rapid breathing; sunken eyes; sweating; excessive thirst; troubled breathing with exertion; ulcers, sores or white spots in mouth; unsteadiness or awkwardness; unusual bleeding or bruising; unusual tiredness or weakness; weakness in arms, hands, legs or feet; wheezing.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.